Clinical Trials
82 trialsNCT02696993 2026-05-20
Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT02444741 2026-05-15
Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT07579195 2026-05-14
Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial
University of Washington
Phase 1/2 Not yet recruiting
NCT03604978 2026-05-13
Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT03767582 2026-05-11
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT07578467 2026-05-11
Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs
University of Pennsylvania
Phase 1/2 Not yet recruiting
NCT01891318 2026-05-08
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
Case Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT04194554 2026-05-01
ASCLEPIuS
University of Michigan Rogel Cancer Center
Phase 1/2 Active not recruiting
NCT07535463 2026-04-17
A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT05987644 2026-04-08
DURABLE
Hoosier Cancer Research Network
Phase 1/2 Recruiting
NCT03508752 2026-03-27
Neurocognitive Decline in Patients With Brain Metastases
University of Texas Southwestern Medical Center
Phase 1/2 Active not recruiting
NCT05789589 2026-03-04
ADORATION
Baptist Health South Florida
Phase 1/2 Recruiting
NCT04785287 2026-03-03
Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04923542 2026-02-06
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Recruiting
NCT04711824 2025-12-23
SOLARA
Hoosier Cancer Research Network
Phase 1/2 Recruiting
NCT04536805 2025-12-08
REPAIR
Institut Cancerologie de l'Ouest
Phase 1/2 Recruiting
NCT06238921 2025-12-05
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Recruiting
NCT04021043 2025-12-03
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT06439888 2025-12-01
LySATRA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT00492817 2025-10-24
Evaluation of Single Session Stereotactic Body Radiotherapy
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04977375 2025-09-03
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
Cedars-Sinai Medical Center
Phase 1/2 Recruiting
NCT03383302 2025-08-01
STILE
Royal Marsden NHS Foundation Trust
Phase 1/2 Completed
NCT06940921 2025-04-27
SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases
First Affiliated Hospital of Chongqing Medical University
Phase 1/2 Active not recruiting
NCT03169764 2025-02-24
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03169790 2025-02-24
QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03167164 2025-02-21
QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03167177 2025-02-21
QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03169738 2025-02-21
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03169777 2025-02-21
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03175666 2025-02-21
QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03197571 2025-02-21
QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03197584 2025-02-21
QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT06725121 2024-12-16
MacroTrans
University Health Network, Toronto
Phase 1/2 Recruiting
NCT01217411 2024-11-19
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT04220775 2024-11-07
Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04098432 2024-09-23
CA209-9KH
University Hospital Hradec Kralove
Phase 1/2 Completed
NCT03050554 2024-08-09
SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)
University of California, San Diego
Phase 1/2 Terminated
NCT02085304 2024-04-19
Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM
St. Joseph's Hospital and Medical Center, Phoenix
Phase 1/2 Terminated
NCT02052648 2024-03-27
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Lumos Pharma
Phase 1/2 Completed
NCT02581787 2024-03-27
SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer
Stanford University
Phase 1/2 Completed
NCT02782715 2024-03-20
Microwave Ablation With MRI-Guided SBRT Boost in Renal Cell Carcinoma
University of Wisconsin, Madison
Phase 1/2 Terminated
NCT06243003 2024-02-07
WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases
Fudan University
Phase 1/2 Recruiting
NCT03749460 2023-12-29
Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers
University of Washington
Phase 1/2 Completed
NCT03340974 2023-12-15
Pilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer
Galera Therapeutics, Inc.
Phase 1/2 Completed
NCT03618134 2023-11-18
Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner
Jonsson Comprehensive Cancer Center
Phase 1/2 Terminated
NCT02407171 2023-10-31
Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
Yale University
Phase 1/2 Completed
NCT03399552 2023-10-23
Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT05451173 2023-10-03
Combining ICI With SBRT or HypoFrx-RT for ES NSCLC
Xuanwu Hospital, Beijing
Phase 1/2 Unknown
NCT06040177 2023-09-15
Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
First Affiliated Hospital of Guangxi Medical University
Phase 1/2 Unknown
NCT05915481 2023-06-23
SCARCE
Peking University Third Hospital
Phase 1/2 Unknown